Challenges in Colorectal Cancer, 2nd Edition
March 2008, Wiley-Blackwell
Colorectal cancer is one of the most common forms of cancer in the US and Europe. Thousands of people are diagnosed with the disease every year and nearly half of these die as a result. As colorectal cancer is curable when detected early, a significant proportion of these deaths could be prevented by earlier diagnosis.
Much has changed since the publication of the first edition of this book in 2001: introduction of screening programs, improved diagnosis and surgery for rectal cancer, and advances in adjuvant and palliative medical therapy to name but a few.
Challenges in Colorectal Cancer provides the most up-to-date information on the new and emerging treatments. The second edition looks at the total patient management of this condition and is aimed at the entire medical team caring for those with colorectal cancer. It also contains the latest guidelines on epidemiology and prevention of colorectal cancer, and the application of molecular genetics.
The expanded international editor team present advice on surgical management, including new laparoscopic and endoscopic techniques and the role of the pathologist. They also review hot topics in colorectal cancer treatment, including the role of radiotherapy, options for chemotherapy and new developments in vaccines and immunotherapy.
2 Screening for colorectal cancer - who, when, and how?.
3 What can the pathologist tell the multidisciplinary team about rectal cancer resection?.
4 MRI-directed rectal cancer surgery.
5 Minimally invasive surgery - where are we? Laparoscopic surgery for cancer of the colon and rectum.
6 Minimally invasive surgery - where are we? Is there a role for TEM?.
7 What is the best strategy for the management of hereditary colorectal cancer?.
8 Adjuvant radiotherapy and chemoradiotherapy in the treatment of rectal cancer.
9 Current challenges in the adjuvant therapy of colon cancer.
10 The role of the colorectal nurse specialist in the management of colorectal cancer.
11 The role of the multidisciplinary team in the management of colorectal cancer.
12 Follow-up after colorectal cancer resection: Is it worthwhile?.
13 Chemotherapy of advanced colorectal cancer.
14 Surgery for metastatic disease in colorectal cancer.
15 Palliative care of the colorectal cancer patient.
16 Future directions in the oncological treatment of colorectal cancer.
Professor Herand Abcarian MD FACS, Turi Josefsen Professor and Chairman of the Department of Surgery, University of Illinois College of Medicine at Chicago, USA.
Professor Tim Maughan, Professor of Cancer Studies at the University of Wales, College of Medicine, and Consultant Clinical Oncologist at the Velindre Hospital Swansea. Also Chairman of the All Wales Cancer Network.
Professor Axel Grothey, Mayo Clinic, USA (formerly Professor of Medicine and Oncology at Martin Luther University, Halle, Germany).
- The expanded international editor team reflects the increasing global significance of this disease
- Includes the latest guidelines on epidemiology and prevention of colorectal cancer, such as the application of molecular genetics, and the new strategies for screening
- Presents didactic advice on surgical management, including new laparoscopic and endoscopic techniques and the role of the pathologist
- Gives detailed oncological management, including the role of radiotherapy, options for chemotherapy and new developments in vaccines and immunotherapy
Colorectal Disease, 2007
"A good book looking at the total management of patients with this condition and aimed at the entire medical team caring fro those with colorectal cancer."
Digestive and Liver Disease, 2007
From a review of the first edition:
“More knowledge of molecular biology, better definition of risk groups, better screening, further development of risk- oriented combination therapy, and more meticulous surgery may yield much higher cure rates for colon and rectal cancer. Scholefield’s book is one of the best starting points for a journey through the world of established, new, and evolving treatments for these diseases.”
New England Journal of Medicine, September 2000